Drugs / Danavorexton
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 17 trials | ||||||
| Phase 1 | NCT05180890 | Mar → Nov 2022 | obstructive sleep apnea syndrome | Takeda | Completed | No outcome recorded |
| Phase 1 | NCT05025397 | Sep 2021 → Mar 2022 | — | Takeda | Completed | No outcome recorded |
| Phase 1 | NCT04091438 | Jan → Nov 2020 | idiopathic hypersomnia | Millennium Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04091425 | Nov 2019 → Apr 2020 | obstructive sleep apnea syndrome | Millennium Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03748979 | Nov 2018 → Oct 2019 | narcolepsy | Takeda | Completed | No outcome recorded |
| Phase 1 | NCT03522506 | May → Nov 2018 | — | Takeda | Completed | Mixed |
| Phase 1 | NCT03332784 | Nov 2017 → Sep 2018 | narcolepsy | Takeda | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05814016 | May 2023 → Sep 2024 | obstructive sleep apnea syndrome | Takeda | Terminated | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2019-09-26 | Takeda | Results New Data Presented at World Sleep Congress Demonstrate Early Signs of Efficacy for TAK-925, a Selective Orexin Type-2 Receptor (OX2R) Agonist, in Patients with Narcolepsy Type 1 takeda.com ↗
Early proof of concept study showed TAK-925 was well tolerated in patients with narcolepsy type 1 and increased wakefulness compared to placebo |
All press releases naming this drug 1 release
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | danavorexton | “The orexin 2 receptor-selective agonist danavorexton (TAK-925) has been shown to produce wake-promoting effects in wild-type mice, narcolepsy-model mice, and individuals with...” PMID 36934366 ↗ Mar 2023 |
| Known as | TAK-925 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03748979 ↗ |
| Action | Activate | “TAK-925, is an orexin 2 receptor agonist” NCT03332784 ↗ |
| Modality | Small molecule | “a small-molecule orexin-2 receptor agonist” PMID 36883238 ↗ Sep 2023 |
| Route | Intravenous | “single intravenous administration” NCT03332784 ↗ |